Prognostic Significance of Serum C-Reactive Protein Levels Among Operable Breast Cancer Patients: CRP Levels Among Breast Cancer Patients

Nayab Amir; Amir Iqbal Memon; Sandesh Kumar; Aisha Masroor Bhatti; Zaheera Yousif; Zarlish Khan

doi:10.54393/pjhs.v5i12.2578

Authors

Nayab Amir Department of General Surgery, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Amir Iqbal Memon Department of General Surgery, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Sandesh Kumar Department of General Surgery, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Aisha Masroor Bhatti Department of General Surgery, Suleman Roshan Medical College, Tandoadam, Pakistan
Zaheera Yousif Department of Pharmacology, Peoples University of Medical and Health Sciences for Women, Nawabshah, Pakistan
Zarlish Khan Department of Pharmacognosy, University of Sindh, Jamshoro, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i12.2578

Keywords:

Serum C-Reactive Protein, Breast Cancer, Postoperative Complications, Modified Radical Mastectomy, Prognostic Marker

Abstract

Serum C-Reactive Protein (CRP) levels, an indicator of systemic inflammation, are increasingly recognized for their prognostic value in cancer. In operable breast cancer, elevated CRP levels may correlate with tumor progression, treatment outcomes, and survival. Objective: To determine the outcome of the raised serum CRP among operable breast cancer patients. Methods: This prospective cohort study was conducted on 126 women of 20-60 years of age with a lump in the breast, bloody or serous nipple discharge ≥ 6-week duration and diagnosed as a case of operable breast cancer on histopathology and were selected for modified radical mastectomy. Patients were divided into 2 groups according to CRP levels (Raised; Group A vs normal; Group B). Results: In Group A (17.5%) cases had wound infections, 16 cases (25.4%) of seroma, and 10 cases (15.9%) of flap necrosis. In contrast, Group B had a lower incidence of these complications, with 4 cases (6.3%) of wound infections, 8 cases (12.7%) of seroma, and 5 cases (7.9%) of flap necrosis. In terms of pain severity, all 63 patients (100.0%) in Group A reported moderate pain, with no cases of severe pain and in Group B, 48 patients (76.2%) experienced moderate pain, and 15 patients (23.8%) reported severe pain (p-0.004). Prolonged Hospital stay was (25.4%) cases of group A and in Group B (49.2%) cases had prolonged hospital stays. Conclusion: Patients with elevated CRP levels are more likely to experience postoperative complications, such as wound infection, seroma formation, and flap necrosis, compared to patients with normal CRP levels.

References

Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. JNCI: Journal of the National Cancer Institute. 2019 Dec; 111(12): 1298-306. doi: 10.1093/jnci/djz090.

Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pacific Journal of Cancer Prevention. 2016; 17(sup3): 43-6. doi: 10.7314/APJCP.2016.17.S3.43.

Angahar LT. An overview of breast cancer epidemiology, risk factors, pathophysiology, and cancer risks reduction. MedCrave Online Journal Biology and Medicine. 2017 Jun; 1(4): 92-6. doi: 10.15406/mojbm.2017.01.00019.

Usmani A and Lateef M. Evaluation of C-reactive protein in breast cancer by enzyme linked immunoassay technique. Journal of the Pakistan Medical Association. 2021 Feb; 71: 424-8. doi: 10.47391/JPMA.297.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019 Aug; 30(8): 1194-220. doi: 10.1093/annonc/mdz173.

Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y et al. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. Journal of Clinical Laboratory Analysis. 2019 Jun; 33(5): e22875. doi: 10.1002/jcla.22875.

Watson J, Salisbury C, Banks J, Whiting P, Hamilton W. Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records. British Journal of Cancer. 2019 May; 120(11): 1045-51. doi: 10.1038/s41416-019-0458-x.

Shimura T, Shibata M, Gonda K, Murakami Y, Noda M, Tachibana K et al. Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer. Oncology Letters. 2019 Jun; 17(6): 5139-46. doi: 10.3892/ol.2019.10183.

Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLOS One. 2017 May; 12(5): e0177137. doi: 10.1371/journal.pone.0177137.

Jung SY, Papp JC, Sobel EM, Pellegrini M, Yu H, Zhang ZF. Genetically predicted C-reactive protein associated with postmenopausal breast cancer risk: interrelation with estrogen and cancer molecular subtypes using Mendelian randomization. Frontiers in Oncology. 2021 Feb; 10: 630994. doi: 10.3389/fonc.2020.630994.

Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World Journal of Surgical Oncology. 2011 Dec; 9: 1-6. doi: 10.1186/1477-7819-9-18

Fang CY, Egleston BL, Byrne C, Bohr GS, Pathak HB, Godwin AK et al. Inflammation and breast density among female Chinese immigrants: exploring variations across neighborhoods. Cancer Causes & Control. 2019 Oct; 30: 1113-26. doi: 10.1007/s10552-019-01206-x.

Kaur RP, Banipal RP, Vashistha R, Dhiman M, Munshi A. Association of elevated levels of C-reactive protein with breast cancer, breast cancer subtypes, and poor outcome. Current problems in Cancer. 2019 Apr; 43(2): 123-9. doi: 10.1016/j.currproblcancer.2018.05.003.

Badar F, Mahmood S, Faraz R, Yousaf A, Quader AU, Asif H. Epidemiology of breast cancer at the Shaukat Khanum memorial cancer hospital and research center, Lahore, Pakistan. Journal of College of Physicians and Surgeons Pakistan. 2015 Oct; 25(10): 738-42. doi: 10.2015/JCPSP.738742.

Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Research. 2011 Jun; 13: 1-3. doi: 10.1186/bcr2891.

Moss JL, Liu B, Feuer EJ. Urban/rural differences in breast and cervical cancer incidence: the mediating roles of socioeconomic status and provider density. Women's Health Issues. 2017 Nov; 27(6): 683-91. doi: 10.1016/j.whi.2017.09.008.

Sprague BL, Ahern TP, Herschorn SD, Sowden M, Weaver DL, Wood ME. Identifying key barriers to effective breast cancer control in rural settings. Preventive Medicine. 2021 Nov; 152: 106741. doi: 10.1016/j.ypmed.2021.106741.

Dahri FJ, Awan MS, Qazi AR, Khaskheli NM, Soomro IA. Early wound complications following modified radical mastectomy with axillary clearance. Journal of Surgery Pakistan (Int). 2011 Oct; 16: 4.

Shah S, Shah RU, Badar A, Shah M, Ahmad S, Muhammad H. Frequency of Early Post-Operative Complications following Modified Radical Mastectomy (MRM) in patients with Breast Carcinoma. Pakistan Journal of Medical and Health Sciences. 2021; 15(6): 1623-5. doi: 10.53350/pjmhs211561623.

Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A,. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PloS one. 2014 Oct; 9(10): e111306. doi: 10.1371/journal.pone.0111306.